Abstract 6057
Background
Streamlining oncology (Onc) and specialist palliative care (SPC) into integrated patient (pt) care is increasingly a gold standard of optimized cancer care. The ways that integrated Onc/SPC manifests in clinical practice may change over time. Little is known about factors that drive evolution in integrated care practices.
Methods
From a pt’s first appointment with outpatient SPC, all visits were chronologically color coded for Onc, SPC, and Neutral (e.g. emergency) or joint visits (Onc/SPC same day). Visual Graphic Analysis revealed 4 patterns of integration (Onc only; SPC only; CONCurrent: permanent exchange of Onc and SPC, ≥5 switches, joint visits; SEGmented: alternating periods of Onc or SPC, <4 switches), independent researchers approved reliability of patterns definitions. Data from 2006-2009 (presented 34-ESMO 2009) were compared with 2016-2017. Explanatory factors for patterns evolution were derived from multi-professional, consensual discussion reviewing descriptive statistics (e.g. impact of inpt admission on patterns, pattern stability over 3 months intervals, anticancer treatment administered by SPC, pt characteristics) and further explored in the data.
Results
345 pts from 2006-09 and 64 from 2016 met eligibility criteria and were included. CONC occurred in 18% in 2006-09 and 45% in 2016 (Χ2 (1, N = 409) = 22.66, p < .001)], and 14% vs 50% remained in the CONC pattern comparing 3 months intervals. Elimination of inpt visits left 3/4 of patterns unchanged. A double-boarded Onc/SPC physician saw 94% of pts in the 2016 sample and prescribed systemic anticancer treatment in > 1/3 of these visits, 77% of these pts were in the CONC Pattern. Joint Onc/SPC visits were increasing over time, also (bi-)weekly alternating visits by Onc and SPC (double-boarded). Pts of CONC had complex and high needs for palliative interventions, were in phase I studies, or refused standard anticancer treatment, but accepted later.
Conclusions
Concurrent Onc/SPC is an increasing and consistent pattern, not explained by mere bed availability. Prescribing anticancer therapy by a double-boarded physician may foster integration. Further research may determine how CONC affects pt outcomes and the influence of pt and physicians’ characteristics.
Clinical trial identification
Legal entity responsible for the study
Cantonal Hospital St.Gallen.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4942 - Analytical validation of OncoMasTR, a multigene test for predicting risk of distant recurrence in hormone receptor-positive early stage breast cancer
Presenter: Tony Loughman
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5641 - Comparing the prognosis of favourable-histology breast cancers between younger women of less than 45 years of age at diagnosis with their older counterparts.
Presenter: Guek Eng Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4448 - TNBC universe: a monocentric retrospective analyses of TILs and AR as prognostic markers
Presenter: Agnese Losurdo
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4755 - Genomic spectrum of Asian breast cancer based on targeted next-generation sequencing in 150 consecutive primary breast cancer
Presenter: Chihwan Cha
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2741 - The Impact of the 21 Gene Recurrence Score (RS) on Chemotherapy (CHemoRx) Prescribing in Hormone Receptor (HR) Positive, Lymph Node Positive (LN+) Early-Stage Breast Cancer (BC) in Ireland: A National, Multi-centre, Prospective Study (CTRIAL-IE 15-34)
Presenter: Anees Hassan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3356 - Lymphocyte-predominant breast cancer has a significant lower mean of absolute neutrophil counts compared to non-lymphocyte-predominant breast cancer: Analyses with 576 cases
Presenter: Da Young Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4020 - Genetic Alterations of Early-Stage Breast Cancers by next-generation sequencing (NGS)
Presenter: Yan Xu
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4924 - Oncotype Dx results in patients _40 years, Does age matters?: new insights
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2646 - Impact of BRCA status on outcomes and survival in high-risk early breast cancers
Presenter: Elodie Klajer
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4516 - Early breast cancer classified as intermediate risk by the Prosigna assay: Characteristics and treatment strategy
Presenter: Nawale Hajjaji
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract